TITLE

2010 - Meta-analysis: Alteplase improves functional outcomes when given within 4.5 hours of stroke onset

AUTHOR(S)
Graham, Glenn D.
PUB. DATE
September 2010
SOURCE
ACP Journal Club;9/21/2010, Vol. 153 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study establishing the relation between time and outcomes to the treatment with intravenous Alteplase in acute stroke. According to the randomized controlled trials (RCTs) by K. R. Lees and colleagues, Alteplase improves functional outcomes when given within 4.5 hours of stroke onset. A chart presenting comparison between Ateplase and placebo, in the treatment of acute stroke is also presented.
ACCESSION #
54115033

 

Related Articles

  • The PROGRESS trial three years later: time for a balanced report of effectiveness. Wennberg, Richard; Zimmermann, Camilla // BMJ: British Medical Journal (International Edition);10/23/2004, Vol. 329 Issue 7472, p968 

    Reports on the results of the three-year PROGRESS trial, which studied perindopril protection against stroke. Findings that blood pressure lowering was safe and effective; Details of the trial; Requirements of the patients who had had a stroke or transient ischaemic attack in the previous five...

  • Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR : A safety and tolerability study. Diener, Hans-Christoph; AlKhedr, Abdullatif; Busse, Otto; Hacke, Werner; Zingmark, Per-Henrik; Jonsson, Niclas; Basun, Hans // Journal of Neurology;May2002, Vol. 249 Issue 5, p561 

    Background and purpose A low-affinity, use-dependent N-Methyl-D-Aspartate (NMDA) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke. The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would...

  • Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. Redfield, Margaret M.; Chen, Horng H.; Borlaug, Barry A.; Semigran, Marc J.; Lee, Kerry L.; Lewis, Gregory; LeWinter, Martin M.; Bouleau, Jean L.; Bull, David A.; Mann, Douglas L.; Deswal, Anita; Stevenson, Lynne W.; Givertz, Michael M.; Ofili, Elizabeth O.; O'Connor, Christopher M.; Felker, G. Michael; Goldsmith, Steven B.; Bart, Bradley A.; McNulty, Steven E.; Ibarra, Jenny C. // JAMA: Journal of the American Medical Association;3/27/2013, Vol. 309 Issue 12, p1268 

    The article presents a study which was conducted to determine the effect of the phosphodiesterase-5 inhibitor sildenafil as compared with clinical status and placebo on exercise capacity in heart failure with preserved ejection fraction (HFPEF). The study was carried out to check if...

  • Hypokalemia, Cardiac Failure, and Reporting NXY-059 Safety for Acute Stroke. Serebruany, Victor L. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2006, Vol. 11 Issue 4, p229 

    The article discusses the efficacy of NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, in treating acute stroke based on the results of two clinical trials. Hemorrhagic transformation occurred in patient subjects treated with NXY-059 compared to those who received placebo. The cardiac...

  • Phase I Clinical Trials Update: January 2009.  // BioWorld Financial Watch;2/16/2009, Vol. 17 Issue 7, p3 

    A chart is presented that lists the Phase I clinical trials conducted in January 2009 including ARRY-300 of Array BioPharma Inc., CS-4945 of Cylene Pharmaceuticals, and ImmuFact IMP321 of Immutep SA.

  • Bitter pill to swallow.  // New Statesman;11/8/2010, Vol. 139 Issue 5026, p38 

    In this article the author discusses homoeopathic medicine in Great Britain. He is against the remedies provided under homoeopathic medicine stating that they work no better than placebos and could be potentially dangerous. The author urges that all homoeopathic remedies be subjected to clinical...

  • Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. Schauer, E.; Wronski, R.; Patockova, J.; Moessler, H.; Doppler, E.; Hutter-Paier, B.; Windisch, M. // Journal of Neural Transmission;Jul2006, Vol. 113 Issue 7, p855 

    All attempts to reduce neuronal damage after acute brain ischemia by the use of neuroprotective compounds have failed to prove efficacy in clinical trials so far. One of the main reasons might be the relatively narrow time window for intervention. In this study 2 different tissue culture models...

  • Recombinant Activated Factor VIIa: Phase III Trial Fails to Show Clinical Benefit. Segal, Alan Z. // Neurology Alert;Jul2008, Vol. 26 Issue 11, p86 

    RANDOMIZED STUDIES OF NEUROPROTECTIVE AGENTS for ischemic stroke have resulted in a series of failures, as multiple agents, promising in animal models, have failed when applied to human subjects. By contrast, intracerebral hemorrhage (ICH), has been somewhat a "neglected stepsister" when...

  • Cerebrovascular Accidents in Elderly People Treated with Antipsychotic Drugs: A Systematic Review. Emilio Sacchetti; Turrina, Cesare; Valsecchi, Paolo // Drug Safety;2010, Vol. 33 Issue 4, p273 

    After 2002, an association between stroke and antipsychotic use was reported in clinical trials and large database studies. This review considers previous quantitative reviews, newly published clinical trials, and recent observational cohort and case-control studies, and focuses on the clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics